Table 1. Patient characteristics.
| Characteristics | n=75 |
|---|---|
| Median age, years (range) | 68 (41–85) |
| Age >70 years, n (%) | 32 (42.5) |
| Male, n (%) | 34 (45) |
| WHO performance status, n (%) | |
| 0–1 | 62 (82.5) |
| ⩾2 | 13 (17.5) |
| Myeloma type, n (%) | |
| IgG | 46 (61.5) |
| IgA | 15 (20) |
| Light chain | 14 (18.5) |
| ISS stage, n (%) | |
| I–II | 55 (73.5) |
| III | 20 (26.5) |
| FISH analysis, n (%) | |
| Standard risk | 28 (78) |
| High risk | 8 (22) |
| Renal failure, n (%) | 7 (9) |
| LDH (U/l), n (%) | |
| Normal | 53 (71) |
| Above normal range | 22 (29) |
| Hb level (g/dl), n (%) | |
| <10 | 19 (28) |
| ⩾10 | 49 (72) |
| Platelet count at enrolment ( × 109/l), n (%) | |
| <100 | 6 (8) |
| ⩾100 | 62 (92) |
| Previous lines of therapy, n (%) | |
| 1 | 40 (53) |
| 2 | 22 (29) |
| 3 | 3 (8) |
| 4 | 7 (10) |
| Prior treatment regimens | |
| Previous alkylating, n (%) | 52 (69) |
| Previous anthracyclines, n (%) | 22 (29) |
| Previous thalidomide, n (%) | 43 (57) |
| Previous bortezomib, n (%) | 35 (46.5) |
| Previous lenalidomide, n (%) | 41 (54.5) |
| Duration of lenalidomide treatment, median (range) | 10 (2–42) |
| Previous lenalidomide and bortezomib, n (%) | 15 (20) |
| Refractory to IMIDs, n (%) | 24 (32) |
| Previous ASCT, n (%) | 33 (44) |
| Disease history longer than 3 years, n (%) | 44 (59) |
Abbreviations: ASCT, autologous stem cell transplant; FISH, fluorescence in situ hybridization; Hb, haemoglobin; Ig A, immunoglobulin A; Ig G, immunoglobulin G; IMID, Immunomodulatory drug; ISS, International Staging System for Multiple Myeloma criteria; LDH, lactate dehydrogenase; WHO, World Health Organization.